M & A

Both companies announced that during special meetings on Jan. 29, their shareholders voted nearly unanimous support for Kimberly-Clark’s $48.7bn acquisition proposed in November at $3.50 per share plus 0.14625 share for each Kenvue share.

Revenue from Sun Pharma’s innovative medicines business overtook its generics business for the first time ever in Q2 of fiscal year 2026 and North American CEO Richard Ascroft is focused on maintaining the growth momentum.

Wonderbelly reached market in 2022 and has notched nationwide footprint through major retailers over the years, Target stores starting in March 2023, CVS since June 2024 and Walmart since May 2025.

Abbott started 2026 as it ended 2025 – with major regulatory breakthroughs for pulsed field ablation innovations, boosting its EP credentials in the US and EU. It also broadened its IVDs platform by adding cancer detection and screening company Exact Sciences in a deal expected to close in Q2.

VP Elizabeth Naldi-Jacob spoke with Scrip at the J.P. Morgan Healthcare Conference about Merck’s business development priorities and the company’s strategy for winning deals.

The US giant is narrowing its focus on obesity and cancer.

Sun terms reports of acquisitive interest in Organon as "speculative," at least for now. Bankers see a potential transaction fit the profile of a 'typical’ Sun deal, which if it occurs also catapults the Indian firm’s foray into biosimilars.

It’s time for In Vivo's 18th annual Deals of the Year contest. We've chosen 15 nominees across three categories – Top M&A, Top Alliance, and Top Financing – and now it’s your turn to pick the winners.

An interactive look at medtech and diagnostics deals made during December 2025. Data courtesy of Biomedtracker.

CEO Vas Narasimhan told attendees at J.P. Morgan that the firm’s considerable financial firepower means it will continue to do “value-creating bolt-ons like you saw last year."

Transaction adds sterile injectable manufacturing and strengthens the company’s US-based operations.

Taking full ownership of its Hulio adalimumab biosimilar is among a trio of positive updates from India’s Biocon.